Fact-checked by Grok 2 weeks ago

David Nutt


David John Nutt (born 16 April 1951) is a British neuropsychopharmacologist and psychiatrist specializing in the effects of psychoactive substances on the brain and in neuropsychiatric conditions including addiction, anxiety, and sleep disorders.
As the Edmond J. Safra Professor of Neuropsychopharmacology and head of the Centre for Neuropsychopharmacology at Imperial College London, Nutt has advanced empirical methods for evaluating drug harms through multicriteria decision analyses, notably ranking alcohol as the overall most harmful substance due to its physical harm, dependence potential, and societal costs.61462-6/abstract)
His commitment to evidence-based drug classification over political considerations led to his dismissal as chair of the UK's Advisory Council on the Misuse of Drugs in 2009 by Home Secretary Alan Johnson, after he publicly critiqued government decisions that prioritized perceived risks over scientific data, such as reclassifying cannabis despite evidence of lower harm relative to alcohol or tobacco.60301-7/abstract)
Nutt's work extends to pioneering research on psychedelics for therapeutic applications and advocacy for policy reforms grounded in causal assessments of harm reduction, earning him the 2013 John Maddox Prize for promoting science against opposition.

Background

Early life and education

David John Nutt was born on 16 April 1951 in England. He completed his secondary education at Bristol Grammar School before gaining admission via the 11-plus examination. Nutt was awarded an open scholarship in medicine at Downing College, University of Cambridge, where he began his undergraduate studies. He subsequently undertook clinical medical training at Guy's Hospital Medical School in London. Following his medical qualification, Nutt pursued postgraduate training in , attaining membership of the Royal College of Physicians (MRCP). He then specialized in , completing his training at the , where he earned a (DM) degree.60700-X/fulltext) This foundational period established his expertise in neuropsychopharmacology through structured clinical and research-oriented education.

Academic Career

Key positions and affiliations

Nutt established and led the Unit at the upon returning to the in 1988, serving as Professor of and head of the unit until 2009. In this role, he also headed the Department of Community-Based , focusing on psychopharmacology within addiction and brain sciences contexts. In 2009, Nutt was appointed the Edmond J. Safra Professor of Neuropsychopharmacology at , a position he has held continuously in the Division of Sciences, Faculty of . Concurrently, he directs the Neuropsychopharmacology Unit, overseeing operations in neuropsychopharmacological research and related brain science initiatives. Nutt maintains additional academic affiliations, including visiting professorships at the in the UK and in the , which facilitate collaborative extensions of his institutional work.

Core research themes

David Nutt's research in neuropsychopharmacology has centered on elucidating the neural mechanisms underlying psychoactive substance effects, with a focus on processes and their modulation by systems. His work has emphasized the role of inhibitory neurotransmission, particularly GABAergic pathways, in disorders involving compulsive behaviors, as demonstrated through studies linking GABA-A receptor dysregulation to conditions like gambling disorder. Nutt has also explored and GABAergic imbalances in using techniques to quantify synaptic alterations. A core theme involves integrating pharmacological interventions with imaging to assess cognitive and behavioral outcomes in psychiatric conditions, including and anxiety. For instance, Nutt's investigations have utilized functional MRI platforms to probe neuropharmacological responses, aiming to map how substances alter connectivity and . This approach prioritizes empirical quantification of substance impacts on neural circuits over subjective or societal valuations, facilitating objective evaluations of therapeutic potential and risk. Nutt's empirical framework underscores causal links between molecular targets—like and serotonin receptors—and observable harms or benefits, drawing on longitudinal data from human and preclinical models to inform substance classification based on verifiable neurobiological rather than external influences. His contributions extend to modeling as a dysregulated reward-inhibition interplay, incorporating dynamics to predict vulnerability and response to treatments.

Drug Harm Assessments

Methodology and key studies

David Nutt's initial approach to quantifying drug harms appeared in a 2007 study published in The Lancet, which developed a nine-category matrix to evaluate 20 substances of potential misuse.60464-4/abstract) The matrix divided harms into three broad domains—physical harm, dependence potential, and social harms (encompassing crime, family disruption, economic costs, community damage, and international damage)—with experts using a Delphi-like process to score each drug on a 0–3 scale per category, aggregating to overall harm ratings.60464-4/abstract) Scores drew from epidemiological data on mortality, morbidity, and addiction rates, alongside consultations with pharmacologists, psychiatrists, and policy experts, aiming to provide a systematic, evidence-informed framework rather than relying on subjective or political classifications. This method evolved in the 2010 Lancet study, which applied multicriteria decision analysis (MCDA) to assess harms from 20 drugs in the UK context.61462-6/abstract) MCDA involved selecting 16 specific criteria—nine for individual harms (e.g., acute physical damage, chronic physical disease, intravenous harm, psychological dependence, social harm) and seven for harms to others (e.g., physical harm via crime, economic costs, environmental damage)—scored quantitatively by members of the Independent Scientific Committee on Drugs (ISCD) using a 0–100 scale informed by peer-reviewed literature and expert consensus.61462-6/abstract) Weights for criteria were derived through paired comparisons by ISCD members and external specialists, enabling a structured aggregation that addressed limitations in the 2007 matrix, such as inconsistent weighting and less discrimination between drugs. Subsequent refinements incorporated drug prevalence and user population estimates to adjust for societal impact, using data from national surveys like the British Crime Survey and health statistics to scale harms by exposure levels. These methods relied on verifiable sources including clinical trials, reports, and longitudinal studies for scoring inputs, with transparency emphasized through published matrices and sensitivity analyses to test robustness against varying expert judgments.61462-6/abstract)

Findings on relative harms

In the 2010 multicriteria by Nutt and colleagues, emerged with the highest overall harm score of 72 out of 100, attributed to its widespread prevalence amplifying societal impacts, followed by at 55 and at 54.61462-6/abstract) ranked sixth overall at 26, reflecting significant physical harm despite lower dependence scores compared to illicit opioids.61462-6/abstract) Harm to users specifically placed at the top with 37, at 34, and at 32, whereas scored 26, primarily from acute intoxication and chronic disease risks.61462-6/abstract) received an overall score of 20, lower than both and , with minimal scores in lethality and intravenous harm but moderate dependence potential.61462-6/abstract) Substances like and () scored notably low at 7 and 9 overall, respectively, due to limited evidence of severe physical damage or high dependence, contrasting with higher-ranked Class A drugs such as (27).61462-6/abstract) Anabolic steroids and magic mushrooms tied for the lowest at 6-9, with harms concentrated in specific contexts like misuse rather than broad societal effects.61462-6/abstract) Subsequent adaptations of the framework in international contexts, such as and , replicated 's top ranking and the relative positioning of below legal drugs like , emphasizing prevalence-adjusted totals in harm calculations.

Scientific and methodological critiques

Critics of Nutt's multi-criteria decision analysis (MCDA) framework have highlighted its reliance on subjective expert judgments, particularly in the process where panels assign and adjust scores for harm criteria. Rolles and Measham (2011) argue that this approach is vulnerable to error due to over-reliance on value judgments, lacking measures for weightings that prioritize certain harms over others, such as social versus individual impacts. They further contend that aggregating heterogeneous criteria—like physical , dependence, and —into a single overall harm score conflates non-commensurable elements, reducing analytical precision and potentially misrepresenting relative risks. Specific methodological concerns include the underemphasis on acute and long-term risks for certain substances. For instance, in assessing (), commentators have noted grounds for concern that and associated cognitive deficits—evidenced in complex literature on serotonin system disruption, memory impairment, and mood alterations—may be downplayed relative to other drugs like or , where dependence and acute harms receive higher weightings. This stems from the framework's focus on averaged expert scores, which critics argue insufficiently accounts for variability in evidence interpretation, such as ecstasy's lower dependence rating despite potential for repeated use amplifying neurotoxic effects. Debates persist over omitted factors, including gateway effects, polydrug interactions, and enforcement costs, which some rebuttals claim distort assessments by isolating "intrinsic" harms from broader societal dynamics. Nutt has countered these by emphasizing data-driven separation of drug-specific effects from influences, citing consistent rankings from panels in 2007 that validated weights without significant divergence. Nonetheless, detractors maintain that such exclusions limit the model's applicability to real-world harm profiles, where and context modulate outcomes.

Policy Advocacy and Government Roles

Advisory appointments

David Nutt served as a member of the UK's Advisory Council on the Misuse of Drugs (ACMD) prior to his elevation to chairmanship. In May 2008, announced his appointment as chair designate, with Nutt assuming the role in October 2008. As ACMD chair, Nutt oversaw the council's mandate to deliver independent expert advice to the on the control of dangerous or harmful substances. This encompassed reviewing scientific evidence on drug harms to recommend classifications and schedulings under the , which categorizes substances into Classes A, B, and C based on potential for misuse and associated risks. The process involved evaluating pharmacological profiles, dependence liability, toxicity, and societal impacts through subcommittees and formal evidence submissions. Nutt's tenure emphasized rigorous, data-driven assessments for policy inputs, including interactions with departments to ensure recommendations aligned with empirical findings on effects prior to 2009. The ACMD under his prioritized multidisciplinary input from , , and experts to inform controls on both novel and established substances.

The "Equasy" paper and equine sports analogy

In February 2009, David Nutt published the short article "Equasy – An overlooked addiction with implications for the current debate on drug harms" in the Journal of Psychopharmacology. In it, he coined the term "equasy," a portmanteau of "equine" and "ecstasy," to describe what he portrayed as an addictive pursuit of horse riding, using the analogy to challenge perceived inconsistencies in how society and policymakers assess and regulate risks from recreational activities versus illicit drugs. Nutt argued that equasy exemplifies how high-risk behaviors, including acute injuries and fatalities, are tolerated when culturally accepted, contrasting this with the absolutist stance on substances like MDMA (ecstasy). The piece aimed to advocate for harm-based, evidence-driven drug classification over moralistic prohibition, emphasizing that policy should reflect comparative empirical dangers rather than symbolic deterrence. Nutt grounded the comparison in a modified 9-point harm assessment scale, previously applied to drugs, rating categories such as acute personal harm, harm, dependence, and societal costs. For acute harm to users, he cited horse riding's rate of one serious injury per 350 episodes—drawing from hospital data showing around 100 deaths and thousands of injuries annually—versus ecstasy's rarer one per episodes, with ecstasy-related deaths numbering 50–60 yearly amid an estimated 500,000–800,000 users. Dependence potential was scored low for both (+1), but equasy's physical toll (e.g., joint damage) and social harms (e.g., costs of maintaining horses) were highlighted as comparable or exceeding those of occasional use, which lacks strong evidence of long-term cognitive deficits at typical doses. Nutt stressed these statistics underscore ecstasy's relative safety in controlled, non-adulterated contexts, urging reevaluation of its Class A status under the 's Misuse of Drugs Act. The publication elicited swift criticism from political figures and equine organizations, who accused Nutt of trivializing ecstasy's dangers and disrespecting legitimate sports. publicly condemned the analogy as inappropriate, demanding an for implying between a voluntary pastime and a , amid ongoing debates over reclassification following earlier ACMD reviews. Nutt issued a partial retraction, regretting the "equasy" terminology for potentially offending riders but reaffirming the validity of the risk data and policy critique. Bodies like the British Horse Society and federations decried the framing as derogatory, arguing it ignored contextual differences in , , and intent between sporting pursuits and consumption.

Dismissal from ACMD and policy implications

On 30 October 2009, David Nutt was dismissed as chair of the Advisory Council on the Misuse of Drugs (ACMD) by , who stated that he had "lost confidence" in Nutt's ability to provide impartial advice due to public statements perceived as undermining government policy. Nutt's comments included assertions that caused greater societal harm than or in certain metrics, and that drugs like and posed lower risks than , which conflicted with official classifications and decisions such as the 2009 recriminalization of to Class B. Johnson cited Nutt's role as requiring discretion, arguing that such public critiques distorted scientific evidence in the eyes of policymakers. The dismissal prompted immediate backlash within the , including the resignations of at least five ACMD members in , highlighting concerns over the politicization of expert advice. In response, Nutt established the Independent Scientific Committee on Drugs (later rebranded as Drug Science) on 15 January 2010, positioning it as an alternative body to deliver evidence-based assessments free from governmental influence. This organization aimed to rank drug harms using multicriteria analysis, critiquing the ACMD's perceived alignment with punitive rather than empirical priorities. The event underscored a persistent rift between empirical harm assessments and drug policy, which prioritized moral and political signaling over data-driven reforms; despite Nutt's analyses, classifications like those for , , and remained unchanged through subsequent governments. A decade later, in 2019, policy reviews confirmed minimal shifts, with ongoing reliance on Class A/B/C frameworks that Nutt and others argued ignored relative harms, such as alcohol's unclassified status despite high societal costs exceeding those of many scheduled drugs. This reinforced critiques that lawmaking favored punitivist approaches, sidelining causal evidence on and outcomes, and eroded trust in advisory bodies by signaling that dissenting risked exclusion.

Psychedelic and Novel Therapy Research

Development of research programs

In 2008, following his appointment at , David Nutt co-founded the Beckley/Imperial Psychedelic Research Programme in collaboration with of the Beckley Foundation, marking the inception of structured psychedelic investigations at the institution. This initiative built upon Nutt's prior expertise in neuropsychopharmacology and aimed to systematically explore the brain effects of psychedelics through controlled studies, shifting emphasis from historical recreational associations toward potential therapeutic applications. The programme evolved over the subsequent decade, incorporating advanced techniques to examine substances including , , and DMT under regulated conditions, with a focus on elucidating neural mechanisms relevant to disorders. By 2019, this groundwork culminated in the formal launch of the Centre for Psychedelic Research on , recognized as the world's first dedicated center for such studies, led by Robin Carhart-Harris with Nutt serving as the Edmond J. Safra in Neuropsychopharmacology. This development provided historical continuity to psychedelic inquiry, reviving protocols from the and —when LSD and similar compounds showed promise in psychiatric settings before regulatory prohibitions largely halted research—now updated with contemporary ethical frameworks, randomized controlled trials, and multimodal imaging. Funding for these efforts has included grants from the Beckley Foundation and charitable donations, enabling interdisciplinary collaborations with researchers such as David Erritzoe to expand infrastructure for preclinical and clinical explorations.

Clinical trials and empirical outcomes

Nutt co-authored findings from a 2016 open-label feasibility study at involving 12 patients with , where a single 10 mg or 25 mg dose of administered with psychological support led to rapid and sustained antidepressant effects; at 1-week follow-up, 8 of 12 patients showed a greater than 50% reduction in depression scores on the Quick Inventory of Depressive Symptomatology (QIDS), with effects persisting in some up to 3 months, though the small sample and lack of placebo control limited causal inferences. A 2021 he co-led compared two 25 mg doses plus psychological support against a 6-week course of in 59 patients with ; both arms showed significant symptom reductions, but yielded higher remission rates (37% vs. 18% at week 6, per Montgomery-Åsberg Depression Rating Scale criteria) and greater improvements in well-being and environmental connectedness, despite comparable response rates, with the trial noting limitations from its modest sample size and absence of blinding for 's subjective effects. Functional MRI (fMRI) data from psilocybin-treated patients, analyzed in Nutt-affiliated research, revealed acute decreases in integrity and increased global brain , correlating with symptom relief; post-treatment scans indicated persistent desynchronization and enhanced plasticity-like changes, such as reduced reactivity to negative stimuli, with effect sizes (e.g., Cohen's d > 1 for metrics) suggesting mechanisms beyond , though longitudinal causality remains unproven due to small cohorts (n<60) and confounding from expectancy. In 2023-2024, Nutt supported early-phase designs for psilocybin trials targeting addiction, including a UK government-funded study at Imperial for opioid use disorder relapse prevention (ISRCTN10232579), combining 25 mg psilocybin with therapy to assess craving reduction and abstinence rates over 6 months in 100 participants, building on prior addiction pilot data but pending empirical outcomes; similarly, a gambling disorder protocol initiated fMRI probes of psilocybin's impact on reward processing, hypothesizing disruption of compulsive circuits, with recruitment planned for 2024 but no completed results as of late 2025. These efforts reference Australia's 2023 regulatory approvals for psilocybin in treatment-resistant depression as a comparative benchmark, where clinician-prescribed use showed preliminary remission in 20-30% of cases, underscoring the need for larger, controlled Nutt-led validations amid sample and generalizability constraints.

Therapeutic claims versus evidence gaps

David Nutt has described psychedelics as possessing revolutionary therapeutic potential for psychiatric disorders, asserting in his 2023 book Psychedelics: The Revolutionary Drugs That Could Change Your Life that society stands "on the cusp" of a major shift in mental health treatment through these substances. He emphasizes their capacity to induce profound neuroplasticity and psychological insights, potentially outperforming conventional antidepressants in conditions like depression and PTSD. However, such assertions are tempered by empirical limitations in the supporting data, including persistently small sample sizes—often under 100 participants per arm—and reliance on short-term follow-ups rarely exceeding six months, which hinder assessments of durability and generalizability. Further scrutiny reveals inconsistencies in placebo controls, as psychedelic trials frequently suffer from blinding failures due to the drugs' unmistakable subjective effects, such as intense perceptual alterations, leading participants and therapists to accurately guess assignments in over 90% of sessions. This compromises causal attribution, inflating apparent efficacy through expectancy biases rather than isolated pharmacological action. Critiques highlight a risk of hype, akin to the "Pollan effect" from popularized narratives that amplify optimism while downplaying methodological flaws, potentially skewing public and investor expectations beyond the nascent evidence base. Adverse events remain understudied, particularly in vulnerable populations, with conditions like hallucinogen persisting perception disorder (HPPD)—involving chronic visual disturbances—and potential dependency patterns in those with preexisting psychiatric vulnerabilities receiving insufficient long-term scrutiny in trials. Establishing robust causality demands large-scale randomized controlled trials (RCTs) to isolate effects from contextual confounds, yet the field's progression toward such designs lags, underscoring the gap between promotional claims and verifiable therapeutic superiority.

Commercial and Organizational Ventures

Founding of Drug Science

Drug Science was established in January 2010 by , shortly after his dismissal from the chairmanship of the UK's (ACMD) in November 2009, which stemmed from his public criticisms of government drug classification policies as ideologically driven rather than evidence-based. The organization was launched as an independent scientific body to counter perceived politicization in official drug advice, with an initial focus on assembling experts to review scientific evidence on drug harms without governmental constraints. The nonprofit's mission centers on producing and disseminating impartial, data-driven analyses of drugs to advocate for reforms grounded in empirical harm assessments, equipping policymakers, media, and the public with information untainted by political or commercial pressures. Organizationally, it operates as a registered UK charity (number 5027633) led by Nutt as founder and chief scientific officer, supported by an executive team handling operations and a scientific committee comprising prominent UK experts in pharmacology, neuroscience, and policy from academia and research institutions. Funding derives primarily from individual donations and philanthropic grants, such as those from the , ensuring operational independence from state or industry sources. Key outputs include detailed reports evaluating the comparative harms of substances like cannabis and alcohol, using quantitative metrics such as physical dependence potential, mortality risks, and societal costs to propose classification alternatives based on scientific benchmarks rather than punitive or moralistic criteria. These publications have contributed to public discourse by highlighting inconsistencies in legal frameworks—for instance, arguing that alcohol's documented harms exceed those of cannabis in several domains—fostering debates on evidence-led policy without reliance on government affiliations.

GABA Labs and Alcarelle project

In 2019, David Nutt co-founded GABA Labs, a commercial venture aimed at developing novel GABAergic compounds to replicate the desirable social and relaxing effects of alcohol while eliminating associated health risks such as liver toxicity, hangovers, and dependence. The company focuses on biomimetic molecules that selectively target GABA_A receptors in the brain—the primary mechanism by which ethanol induces euphoria and disinhibition—without engaging other pathways that cause oxidative stress or metabolic harm. The flagship project, Alcarelle, is a patented synthetic ingredient designed as a non-alcoholic alternative, with Nutt estimating potential market availability by late 2027 pending regulatory approval, including submissions to the as a novel food ingredient. Development began with screening over 90 candidate compounds identified through literature review of , narrowing to three finalists via preclinical neurochemical assays demonstrating selective receptor agonism and dopamine/serotonin release akin to low-dose ethanol. Patents for these Alcarelle formulations were filed starting in 2018, emphasizing causal specificity to for harm reduction in social drinking. GABA Labs markets Alcarelle for integration into non-alcoholic beverages, positioning it as a tool for reducing alcohol-related societal costs—estimated at billions annually from morbidity and lost productivity—by offering equivalent conviviality without caloric load or toxicity. Initial proof-of-concept products like , using plant-derived GABA agonists, have been commercialized to validate consumer appeal, though full-scale empirical trials for Alcarelle's long-term safety and efficacy remain pending, with some experts cautioning that untested selective agonism may overlook off-target neural adaptations or incomplete replication of alcohol's multifaceted pharmacology.

Publications

Major books

Drugs Without the Hot Air: Minimising the Harms of Legal and Illegal Drugs, first published on May 31, 2012, by UIT Cambridge, applies scientific evidence to evaluate the comparative risks of various substances, including alcohol, tobacco, cannabis, and opioids, while critiquing prohibitionist policies for inflating harms through adulteration and criminalization. The book uses quantitative rankings of drug harms, derived from expert assessments, to argue for harm minimization strategies over moralistic approaches, emphasizing data on physical dependence, social costs, and overdose potentials. Revised editions in 2020 and 2022 integrate updated epidemiological data and policy developments, maintaining the core thesis that legal drugs like alcohol cause greater aggregate harm than many illicit ones. In Psychedelics: The Revolutionary Drugs That Could Change Your Life—A Guide from the Expert, released January 1, 2023, by Balance Books, Nutt synthesizes neuropharmacological research on compounds like , , and , highlighting their serotonin receptor agonism and potential to induce neuroplasticity for treating depression and PTSD. Drawing from controlled trials, the monograph details mechanisms such as default mode network disruption and mystical experience correlations with therapeutic outcomes, positioning psychedelics as adjuncts to psychotherapy rather than standalone cures. It advocates regulatory reform based on low toxicity profiles—evidenced by LD50 ratios exceeding 1000 for most psychedelics—contrasting them with conventional antidepressants' modest efficacy rates around 30-50%. Nutt's later works, such as updated iterations of his drug policy analyses in 2024 editions, extend these evidence-driven frameworks to broader brain science applications, offering accessible explanations of neurotransmitter dynamics and addiction circuits for non-specialist readers. These monographs collectively prioritize empirical metrics over anecdotal or ideological narratives, influencing public discourse on substance regulation.

Selected articles and reports

Nutt's 2010 article, "Drug harms in the UK: a multicriteria decision analysis," co-authored with Leslie A. King and Lawrence D. Phillips and published in The Lancet, applied multi-criteria decision analysis to rank 20 drugs by overall harm to users and others, influencing subsequent policy discussions on evidence-based classification despite methodological critiques from prohibition advocates.61462-6/abstract) The paper has garnered over 3,000 citations, underscoring its role in shifting academic and public discourse toward quantitative harm assessments rather than anecdotal or political criteria. In his 2009 commentary "Equasy—an overlooked addiction with implications for the current debate on drug harms," published in the Journal of Psychopharmacology, Nutt introduced the term "equasy" to equate the risks of chronic alcohol use with those of ecstasy, drawing on epidemiological data to argue for consistent harm evaluation across substances amid UK classification reviews. This piece, cited in over 100 subsequent works, amplified calls for reclassifying ecstasy while highlighting alcohol's under-regulated societal costs, contributing to tensions between scientific advisory bodies and government policy. Nutt's 2025 Lancet Psychiatry personal view, "Drug development in psychiatry: 50 years of failure and how to resuscitate it," critiques the stagnation in novel psychiatric pharmacotherapies since the 1970s, attributing it to regulatory hurdles, overreliance on monoamine hypotheses, and industry conservatism, while advocating repurposed serotonergic agents like psychedelics.00370-5/abstract) The article, drawing on historical trial data showing minimal efficacy gains, proposes streamlined trials and brain imaging biomarkers to accelerate innovation, positioning it as a catalyst for reforming psychopharmacology pipelines. Other notable contributions include Nutt's 2019 review "Psychedelic drugs—a new era in psychiatry?" in Dialogues in Clinical Neuroscience, which synthesizes neuroimaging evidence on 5-HT2A receptor mechanisms to support psychedelics' potential in treatment-resistant depression, emphasizing neuroplasticity over traditional antidepressants' limitations. In addiction neuroscience, his co-authored 2020 Cell perspective "Psychedelic Psychiatry's Brave New World" outlines empirical gaps in psychedelic trials while arguing for their disruption of entrenched psychiatric paradigms based on dependency and withdrawal metrics.30282-8) These works, with high citation rates in harm and efficacy debates, underscore Nutt's emphasis on data-driven metrics over consensus-driven orthodoxy.

Honors and Recognition

Awards and distinctions

Nutt was elected a Fellow of the Academy of Medical Sciences (FMedSci) in recognition of his expertise in psychiatry, pharmacology, and brain imaging applications to addiction, neuropsychiatric disorders, sleep, and hypnotics. He holds fellowship in the Royal College of Physicians (FRCP) and the Royal College of Psychiatrists (FRCPsych), distinctions reflecting his clinical and research contributions to neuropsychopharmacology. He is also a Fellow of the British Pharmacological Society (FBPhS). In 2013, Nutt received the John Maddox Prize from Sense about Science and Nature Publishing Group for courageously advancing evidence-based drug classification and policy despite political opposition. The British Association for Psychopharmacology awarded Nutt its Outstanding Contribution Award in 2023, honoring over 30 years of service, including his role as editor of the Journal of Psychopharmacology from 1989 onward. In December 2016, the University of Bath conferred an honorary Doctor of Laws upon Nutt for his influential work on rational drug policy and harm assessment.

Recent Developments and Broader Views

Critiques of psychiatric drug development

In a February 2025 personal view published in The Lancet Psychiatry, David Nutt contended that psychiatric drug development has stagnated for 50 years, yielding few novel mechanisms despite advances in somatic medicine, such as antihypertensive and oncology therapies.00370-5/abstract) He highlighted flawed clinical trial paradigms, including short-duration studies prioritizing symptomatic endpoints over sustained remission or biomarkers of underlying pathology, which obscure true efficacy signals amid high placebo responses averaging 30–40% in depression trials.00370-5/abstract) These designs, Nutt argued, perpetuate incremental "me-too" drugs rather than breakthroughs, as regulatory demands for superiority over existing agents deter investment in unproven targets.00370-5/abstract) Central to Nutt's critique is the dominance of selective serotonin reuptake inhibitors (SSRIs), which meta-analyses indicate provide only modest benefits—standardized mean differences of 0.3 or less versus placebo in mild-to-moderate depression—often failing to exceed thresholds for clinical meaningfulness.00370-5/abstract) This over-reliance stems from the entrenched monoamine hypothesis, yet causal evidence linking serotonin deficits to core symptoms remains weak, with drugs inadequately addressing root processes like impaired neuroplasticity, evidenced by reduced dendritic spine density in postmortem depression brains.00370-5/abstract) Side effect profiles further undermine utility, including 40–70% rates of sexual dysfunction and metabolic disruptions contributing to discontinuation in up to 50% of long-term users.00370-5/abstract) Nutt emphasized that conventional agents neglect causal realism by not targeting modifiable substrates such as synaptic remodeling or inflammatory pathways, where preclinical models show deficits but trials rarely incorporate plasticity metrics like BDNF levels or fMRI connectivity changes.00370-5/abstract) In contrast, meta-analyses of underexplored compounds reveal superior effect sizes (e.g., Cohen's d > 1.0 in select rapid-acting interventions) when assays include neurobiological endpoints, suggesting stalled progress reflects methodological conservatism rather than inherent therapeutic limits.00370-5/abstract) He advocated resuscitating development through adaptive trials integrating causal biomarkers, cautioning that without such shifts, psychiatry risks perpetual reliance on marginally effective palliatives.00370-5/abstract)

Ongoing advocacy and future directions

Nutt has intensified advocacy for regulatory reforms following Australia's July 2023 approvals of for and for PTSD, positioning these as models for shifting from to evidence-assessed therapeutic access. Through Drug Science, he leads campaigns urging reclassification of psychedelics and other substances via harm-based metrics, including 2023 submissions to parliamentary committees calling for reduced barriers to schedule 1 drug research and scheduling reviews to align with clinical potential. In July 2025, Nutt highlighted government endorsement of Advisory Council on the Misuse of Drugs recommendations as a step toward psychedelic integration in treatment. Future research directions encompass psilocybin-assisted trials launched in 2024 at to target opioid addiction relapse, employing controlled dosing to evaluate sustained behavioral changes. commercialization efforts via GABA Labs seek FDA and equivalent approvals for Alcarelle, a patented GABA agonist intended to replicate alcohol's convivial effects sans toxicity, with strategies centered on licensing to non-alcoholic beverage firms for market rollout anticipated post-2025 regulatory clearance. Nutt maintains that drug policies must prioritize causal empirical —such as longitudinal harm rankings—over moral or political biases, decrying prohibition's reliance on unverified assumptions that exacerbate black-market risks while permitting alcohol's normalized toll, evidenced by its top-tier societal damage in validated multi-dimensional scales. He contends this evidentiary disconnect sustains inefficient outcomes, urging frameworks that weigh probabilistic benefits against quantified to supplant ideologically driven restrictions.

Personal Life

Family and interests

Nutt resides in , near , in an ironstone country house on the edge of the Mendips, where the family keeps a grand . He shares the home with two Labrador retrievers, Boris and Sonny. His personal interests include , as evidenced by selections featured on BBC Radio 3's Private Passions programme, which included pieces by , , (specifically the Seventh Symphony), and .

References

  1. [1]
    David Nutt | About | Imperial College London
    David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain ...
  2. [2]
    David Nutt, Author at Psychopharmacology Institute
    Biography. Professor David Nutt is the Edmund J. Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit in the Centre for ...
  3. [3]
    Drug harms in the UK: a multicriteria decision analysis - PubMed
    Nov 6, 2010 · Epub 2010 Oct 29. Authors. David J Nutt , Leslie A King, Lawrence D ... Overall, alcohol was the most harmful drug (overall harm score ...
  4. [4]
    Nutt dismissal in Britain highlights diverging drug views - Nature
    David Nutt, until recently chair of the Advisory Council on the Misuse of Drugs (ACMD), was fired by UK Home Secretary Alan Johnson on 30 October.
  5. [5]
    David Nutt wins the 2013 John Maddox Prize for Standing up for ...
    Nov 4, 2013 · Professor David Nutt is the winner of the 2013 John Maddox Prize for Standing up for Science. The international prize is awarded for courage in promoting ...
  6. [6]
    New wave of psychedelic research yielding "exciting results” for ...
    Apr 3, 2020 · This article was adapted from a press release by Cell. 'Psychedelic Psychiatry's Brave New World' by David Nutt et al., is published in Cell.<|separator|>
  7. [7]
    Celebrity Profile: Prof. David Nutt - Sensi Seeds
    Sep 16, 2025 · Prof. David Nutt is a neuropsychopharmacologist from England. He specializes in the research of psychedelic drugs and their potential involvement in the ...
  8. [8]
    #182 - David Nutt: Psychedelics & Recreational Drugs - Peter Attia
    Nov 1, 2021 · After 11+ entry to Bristol Grammar School, David was awarded an Open Scholarship to Downing College Cambridge and then completed his medical ...<|separator|>
  9. [9]
    https://www.bps.ac.uk/about/who-we-are/honorary-fellows-directory/profile?ID=8dfb56b2-d7f6-e311-88a7-001dd8b721a7
  10. [10]
    Prof. David Nutt > Exeter Psychedelic Studies
    David completed his medical training at Guy's Hospital London, trained in neurology to MRCP, trained to be a psychiatrist in Oxford, and then continued there as ...
  11. [11]
    David Nutt | The Psychiatrist | Cambridge Core
    Jan 2, 2018 · David Nutt is Professor of Neuropsychopharmacology at Imperial College London. He trained at Guy's Hospital and Oxford. His special ...
  12. [12]
    david nutt (0000-0002-1286-1401) - ORCID
    After a period in neurology to MRCP he moved to Oxford to a research position in psychiatry at the MRC Clinical Pharmacology Unit where he obtained his DM. On ...<|separator|>
  13. [13]
    2004: Psychopharmacology Unit | News and features
    Nov 16, 2004 · David Nutt is Professor of Psychopharmacology and Head of the Department of Community-Based Medicine at the University of Bristol. He is a ...
  14. [14]
    David Nutt - UKAAN
    David Nutt is currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit in the Centre for Academic ...Missing: education | Show results with:education
  15. [15]
    Evidence for GABA‐A receptor dysregulation in gambling disorder
    9, David J Nutt. David J Nutt. 1Centre for Neuropsychopharmacology, Division ... GABA‐benzodiazepine receptors in opiate addiction: similarities and differences ...
  16. [16]
    Neuroimaging markers of glutamatergic and GABAergic systems in ...
    In cocaine addiction, GABA levels were reduced in the pACC/dorsomedial ... DR, Hammers A, Nutt DJ, Lingford-Hughes AR. History of cigarette smoking is ...
  17. [17]
    David NUTT | Prof of Neuropsychopharmacology - ResearchGate
    David NUTT, Prof of Neuropsychopharmacology | Cited by 64618 | of Imperial College London, London (Imperial) | Read 1418 publications | Contact David NUTT.Missing: education | Show results with:education
  18. [18]
    Acute increases in synaptic GABA detectable in the living human brain
    Oct 1, 2014 · Nutt a , Anne R. Lingford-Hughes a. Show more. Add to Mendeley. Share. Cite ... Currently, human GABA in vivo neuroimaging research ...
  19. [19]
    Neurobiology of addiction and implications for treatment
    These modulate the. GABA–benzodiazepine receptor, increasing the action of GABA, and so result in greater inhibitory activity in the brain (Nutt &. Malizia, ...
  20. [20]
    Development of a rational scale to assess the harm of drugs of ...
    Our methodology offers a systematic framework and process that could be used by national and international regulatory bodies to assess the harm of current and ...
  21. [21]
    (PDF) Nutt DJ, King LA, Phillips LD. Drug harms in the UK
    Aug 9, 2025 · These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases ...
  22. [22]
    Toward an Improved Multi-Criteria Drug Harm Assessment Process ...
    Aug 20, 2018 · The evidence-based multi-criteria drug harm scale (MCDHS) has been proposed as a way of grounding policy in the actual degree of harmfulness of drugs.
  23. [23]
    The Australian drug harms ranking study - PubMed
    The Australian drug harms ranking study. J Psychopharmacol. 2019 Jul;33(7): ... David Nutt , David Castle. Affiliations. 1 1 Department of Addiction ...
  24. [24]
    The New Zealand drug harms ranking study: A multi-criteria decision ...
    A previously developed MCDA drug harm framework provides a robust method of comparing harms from different drugs (Nutt et al., 2007) and considers harms to both ...
  25. [25]
    Questioning the method and utility of ranking drug harms in drug policy
    Questioning the method and utility of ranking drug harms in drug policy. Int ... Authors. Stephen Rolles , Fiona Measham. Affiliation. 1 Transform Drug ...
  26. [26]
    Assessing drug-related harm - The Lancet
    The literature on ecstasy-related neurotoxicity is complex, as is that on ecstasy-related deficits in cognitive performance regarding such things as the ...Missing: criticisms ranking
  27. [27]
    Professor David Nutt, DM, FRCP, FRCPSYCH, FSB, FMEDSCI
    After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent ...
  28. [28]
    2008: Department of Community Based Medicine | News and features
    May 21, 2008 · ... appointed as the new Chair of the Advisory Council on the Misuse of Drugs ( ACMD). Professor David Nutt has been appointed chair designate ...
  29. [29]
    [PDF] ACMD - Advisory Council on the Misuse of Drugs - GOV.UK
    Sep 11, 2008 · In October 2008, I was appointed as Chairman of the ACMD. I was honoured to take up the position and wish my predecessor, ...
  30. [30]
    About us - Advisory Council on the Misuse of Drugs - GOV.UK
    Its primary purpose is to provide technical advice on classification and scheduling of substances under the Misuse of Drugs Act 1971 and its regulations. For ...
  31. [31]
    [PDF] ACMD Standard Operating Procedure (SOP) for using evidence to ...
    The ACMD makes scheduling recommendations under the Misuse of Drugs. Regulations 2001 (as amended) (Chapter 5) for all drugs controlled under the. Misuse of ...
  32. [32]
    [PDF] ACMD - Advisory Council on the Misuse of Drugs - GOV.UK
    It is currently chaired by ACMD member Professor David Nutt. During the ... Misuse of Drugs Act 1971 (the Act) which states as follows: “ It shall be ...
  33. [33]
    An overlooked addiction with implications for the current debate on ...
    An overlooked addiction with implications for the current debate on drug harms. DJ NuttView all authors and affiliations. Volume 23, ...
  34. [34]
    An overlooked addiction with implications for the current debate on ...
    Aug 7, 2025 · PDF | On Feb 1, 2009, D J Nutt published Equasy - An overlooked addiction with implications for the current debate on drug harms | Find, ...
  35. [35]
    [PDF] Equasy – An overlooked addiction with implications for the current ...
    In recent years, following a systematic review by the. ACMD, ketamine (Nutt and Williams, 2004) has been brought under the act into class C whilst khat ( ...
  36. [36]
    Drugs adviser says sorry over ecstasy article - The Guardian
    Feb 9, 2009 · The home secretary demanded an apology from Dr David Nutt after he said that taking ecstasy was no riskier than riding a horse.Missing: backlash reception
  37. [37]
    UK drugs head apologizes over ecstasy danger quip - Reuters
    Feb 9, 2009 · But Nutt said ecstasy was proportionately less dangerous, causing acute harm only in one in every 10,000 cases, compared to one in 350 cases for ...
  38. [38]
    Equasy? ... Srsly? - The Horse
    Feb 9, 2009 · Professor Nutt (yes, really), decided to equate an addiction to horse riding with the use of Ecstasy. He calls the equine addiction "Equasy."Missing: paper Substance<|separator|>
  39. [39]
    Chief drug adviser David Nutt sacked over cannabis stance
    Oct 30, 2009 · Alan Johnson has sacked Professor David Nutt after the scientist renewed his criticism of the government's drug policies.
  40. [40]
    Prof David Nutt sacked from Advisory Council on the Misuse of Drugs
    Nov 2, 2009 · The Home Secretary, Alan Johnson, asked Prof David Nutt to step down from the ACMD, as he has “lost confidence in your ability to advise me as Chair of the ...
  41. [41]
    Alcohol 'more harmful than heroin' says Prof David Nutt - BBC News
    Nov 1, 2010 · ... David Nutt, the former government chief drugs adviser who was sacked in 2009. It ranked 20 drugs on 16 measures of harm ... harm ranking ...
  42. [42]
    Government drug adviser David Nutt sacked - The Guardian
    Oct 30, 2009 · Professor David Nutt, the government's chief drug adviser, has been sacked a day after claiming that ecstasy and LSD were less dangerous than alcohol.
  43. [43]
    Sacked drugs adviser David Nutt launches rival committee
    Jan 15, 2010 · David Nutt, the scientist sacked as a government adviser by the home secretary, today defiantly launched his own independent committee.<|separator|>
  44. [44]
    Society's inconsistent moral judgements of potentially harmful activities
    Mar 6, 2020 · MDMA is neurotoxic if used to excess. Of course it should be no surprise something is harmful if used to excess – that's precisely what excess ...
  45. [45]
    Little has changed in UK drug policy a decade on from sacking of ...
    Nov 5, 2019 · In 2009, the government came under fire when ACMD chair David Nutt of Imperial College London was sacked for questioning government drug policy in public.
  46. [46]
    Sacked science adviser speaks out - Nature
    Nov 2, 2009 · David Nutt explains what his dismissal means for drugs policy and scientific advice in Britain.
  47. [47]
    Speaking power to truth – the unfortunate case of David Nutt
    Nov 1, 2009 · Nutt's dismissal will undoubtedly have long-term repercussions on the effectiveness with which UK policies prevent people's lives being ...Missing: prior | Show results with:prior
  48. [48]
    Exploring the Science-Policy Interface - ScienceDirect.com
    The sacking of David Nutt from his position as Chair of a UK government science advisory council has thrown the interface between science and policy into sharp ...Missing: prior | Show results with:prior
  49. [49]
    The Beckley/Imperial Psychedelic Research Programme
    Amanda Feilding co-founded the Beckley/Imperial Research Programme with Prof David Nutt in 2008. A decade later, the Beckley/Imperial Psychedelic Research ...<|separator|>
  50. [50]
    Imperial launches world's first Centre for Psychedelic Research
    Apr 26, 2019 · Dr Robin Carhart-Harris. Head of Psychedelic Research, Centre for Neuropsychopharmacology · Professor David Nutt. Edmond J Safra Chair in ...
  51. [51]
    Psychedelic Psychiatry's Brave New World - Cell Press
    Apr 2, 2020 · In the 1950s and 1960s, LSD was widely researched and was consid ... David Nutt is a scientific advisor to COMPASS. Pathways. Robin ...Missing: 60s | Show results with:60s<|control11|><|separator|>
  52. [52]
    Funding - Centre for Psychedelic Research - Imperial College London
    Funding · Resources · Contact us. Professor David Nutt. Together we can achieve more: Donate to our Research Centre. The Centre for Psychedelic Research has ...
  53. [53]
    About the Centre and CIPPRes - Imperial College London
    Led and co-founded by Dr David Erritzoe and Dr David Nutt ... Imperial College's Centre for Psychedelic Research / the broader Division of Psychiatry.
  54. [54]
    Psilocybin with psychological support for treatment-resistant ...
    May 17, 2016 · Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study ... David J Nutt. Affiliations. 1 Centre ...
  55. [55]
    Trial of Psilocybin versus Escitalopram for Depression
    Apr 14, 2021 · One open-label trial and four randomized, controlled clinical trials of psilocybin for depression and anxiety have been conducted. ... Nutt, ...
  56. [56]
    Magic mushroom compound performs as well as antidepressant in ...
    Apr 14, 2021 · Magic mushroom compound performs as well as antidepressant in small study · The results · Dr Robin Carhart-Harris · Professor David Nutt ...
  57. [57]
    Magic mushroom compound increases brain connectivity in people ...
    Apr 11, 2022 · Professor David Nutt, Head of the Imperial Centre for Psychedelic Research ... The research was supported by funding from the Alex Mosley ...
  58. [58]
    Neuroimaging in psychedelic drug development: past, present, and ...
    Sep 27, 2023 · The technology available for neuroscientific research in the 1950s was comparatively primitive by modern standards. ... Nutt & David Erritzoe.Missing: 60s | Show results with:60s
  59. [59]
    ISRCTN10232579: A trial to investigate if psilocybin ... - ISRCTN
    This study will investigate if psilocybin combined with psychological support ('psilocybin therapy') can be helpful in treating people recovering from opioid ...
  60. [60]
    Psychedelic therapy may help break the chains of gambling addiction
    Jan 11, 2024 · Professor David Nutt oversees an early brain scanning study involving gambling stimuli. The results of this work, which have yet to be published ...
  61. [61]
    Landmark UK trial investigate psilocybin for opioid addiction relapse
    Oct 30, 2024 · A government-funded UK trial will investigate psilocybin-assisted psychotherapy for targetting relapses associated with opioid addiction.
  62. [62]
    https://journals.uchicago.edu/doi/10.1086/734585
  63. [63]
    Psychedelics: The revolutionary drugs that could change your life ...
    What's it about? This book is about the science of psychedelics and how they can impact our health by world-renowned, leading authority Professor David Nutt.
  64. [64]
    Psychedelics by David Nutt review – hope or hype? - The Guardian
    Jun 15, 2023 · Psychedelics by David Nutt review – hope or hype? An expert makes the case for psychedelic therapy, but we should beware the 'Pollan effect'
  65. [65]
    Evidence Brief: Psychedelic Medications for Mental Health ... - NCBI
    Psychedelic treatments for mental health and substance use disorders are still in an early phase of development and many gaps in the evidence exist, including ...
  66. [66]
    Therapeutic potential of psychedelic drugs: navigating high hopes ...
    Blinding failed: both participants and therapists correctly identified the treatment assignment group for more than 90% of dosing sessions. Expectancy effects ...
  67. [67]
    The difference between 'placebo group' and 'placebo control': a case ...
    Jul 26, 2023 · ... blinding often fails in practice. We use computational modelling to show how weak blinding, combined with positive treatment expectancy, can ...
  68. [68]
    Mind the Psychedelic Hype: Characterizing the Risks and Benefits of ...
    Dubbed the “Michael Pollan Effect”, such pervasive positive messaging about psychedelics has led to heightened expectations regarding the efficacy of ...
  69. [69]
    Case analysis of long-term negative psychological responses to ...
    Sep 25, 2023 · Criticisms have included that study designs and reporting styles bias positive over negative outcomes.
  70. [70]
    Psychedelic use and psychiatric risks - PMC - NIH
    Oct 24, 2023 · The evidence to date suggests that psychedelics generally have a favorable safety profile (Roscoe and Lozy 2022), but psychedelic trials are ...
  71. [71]
    From Efficacy to Effectiveness: Evaluating Psychedelic Randomized ...
    Apr 15, 2025 · From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.
  72. [72]
    A Systematic Review of Study Design and Placebo Controls in ...
    Oct 22, 2023 · Because of the aforementioned difficulties with blinding and inferring causality in psychedelic RCTs with placebos, comparisons of psychedelics ...
  73. [73]
    About - Drug Science
    Founded in 2010 by Professor David Nutt following his removal from his post as Chair of the Advisory Council on the Misuse of Drugs, Drug Science is the only ...
  74. [74]
    David Nutt: 'The government cannot think logically about drugs'
    Dec 6, 2010 · Its mission statement is to "investigate and review the scientific evidence relating to drugs, free from political concerns", and Nutt has ...
  75. [75]
    Drug Science: Home
    Founded by Professor David Nutt following his removal from post as Chair of the Advisory Council on the Misuse of Drugs, DrugScience is the only completely ...Drug Science Journal · Drug Information · About · EventsMissing: mission | Show results with:mission
  76. [76]
    Re: Why doctors have a moral imperative to prescribe and support ...
    Jan 26, 2022 · I founded and chair the scientific committee of the charity Drug Science, which is funded by individual donations, a grant from Open Society ...Missing: independent funding<|control11|><|separator|>
  77. [77]
    Cannabis - Drug Science
    Alcohol withdrawal can cause seizures or even be life-threatening. What is the law around cannabis? In the UK, cannabis is classified as a Class B drug ...
  78. [78]
    'Gaba is the off switch of the brain': Is it also the answer to better ...
    Feb 19, 2025 · He has been researching alcohol alternatives ever since, and in 2019 he co-founded GABA Labs, which makes Sentia. ... Gaba supplements, Nutt says: ...
  79. [79]
    Fake Alcohol Could Make Drinking Safer. But Experts Are Wary | TIME
    Dec 28, 2021 · How? The answer is in the name of GABA Labs, which was co-founded by David Nutt, a neuropsychopharmacologist who used to lead clinical science ...
  80. [80]
    Synthetic alcohol could be the key to avoiding hangovers - Fortune
    Jul 29, 2023 · Alcarelle aims to target only GABA receptors in the brain, allowing for the release of dopamine and serotonin and nothing more, Nutt maintains.
  81. [81]
    GABALabs – Like alcohol, but better
    Alcarelle is a patentable biomimetic ingredient designed to promote conviviality and relaxation. ... Bar Owner or Mixologist: What factors would encourage you to ...Become a GABA Labs supporter · GABA – the Science · Team · Investors
  82. [82]
    The Quest for a Hangover-Free Buzz - Bloomberg.com
    Jul 16, 2025 · Nutt says Alcarelle could be on the market as soon as the end of 2027. GABA Labs has narrowed its list of molecules down to three finalists and ...
  83. [83]
    Novel ingredient mimics alcohol effects sans drawbacks
    Aug 28, 2024 · Alcarelle is an ingredient developed by GABA Labs to create NA drinks that mimic the calming effects of alcohol.
  84. [84]
    Raise your glasses, to alcosynth? - Ayming UK
    Professor Nutt has patented around 90 different 'alcosynth' compounds. Two of these are now being tested for consumer use through his start-up company ' ...
  85. [85]
    ALCARELLE – Like alcohol, but better
    Alcarelle is a synthetic GABAergic ingredient that can be used to make adult drinks and works as an effective catalyst for conviviality and social interaction.
  86. [86]
    Quenching your thirst for knowledge: SENTIA is the present. Alcarelle
    SENTIA is different to Alcarelle and is intended by GABA Labs as a 'proof-of-concept' drink, available today. In order to demonstrate the potential for a ...
  87. [87]
    Drugs Without the Hot Air: Minimising the harms of legal and illegal ...
    30-day returnsPublication date, May 31, 2012 ; Edition, First Edition ; Language, ‎English ; Print length, 368 pages ; ISBN-10, 1906860165.
  88. [88]
    Drugs without the hot air - Bloomsbury Publishing
    Jan 1, 2022 · Written by renowned psychiatrist, Professor David Nutt, Drugs without the hot air casts a refreshingly honest light on drugs and answers crucial questions that ...
  89. [89]
    Drugs without the hot air: Making sense of legal and illegal drugs
    Accessibility: Learn more ; Publication date: January 16, 2020 ; Edition: Second Edition,Second edition ; Language: English ; File size: 4.6 MB ...<|separator|>
  90. [90]
    Psychedelics: The Revolutionary Drugs That Could Change Your ...
    What's it about? This book is about the science of psychedelics and how they can impact our health by world-renowned, leading authority Professor David Nutt.Missing: 2023 | Show results with:2023
  91. [91]
    Psychedelics: reconnecting the brain to heal the mind - Portland Press
    Mar 26, 2024 · David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in Imperial College London and founder of the charity ...Missing: 60s | Show results with:60s
  92. [92]
    Bookshop - Drug Science
    The autobiography of Professor David Nutt describes his life, distinguished career and scientific achievements, including his research into the human brain and ...Missing: list | Show results with:list
  93. [93]
    an overlooked addiction with implications for the current debate on ...
    Equasy-- an overlooked addiction with implications for the current debate on drug harms. J Psychopharmacol. 2009 Jan;23(1):3-5. ... Author. D J Nutt. PMID ...Missing: David | Show results with:David
  94. [94]
    An overlooked addiction with implications for the current debate on ...
    An overlooked addiction with implications for the current debate on drug harms ... David Nutt. Journal of Psychopharmacology. May 2006.
  95. [95]
    Drug development in psychiatry: 50 years of failure and ... - PubMed
    Author. David J Nutt. Affiliation. 1 Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK. Electronic address: d.nutt@imperial ...<|control11|><|separator|>
  96. [96]
    Psychedelic drugs—a new era in psychiatry? - PMC - PubMed Central
    Psychedelic drugs—a new era in psychiatry? spanish title. french title. David Nutt. David Nutt, DM. 1Author affiliations: Professor of Neuropsychopharmacology ...Missing: 60s | Show results with:60s
  97. [97]
    Professor David Nutt | The Academy of Medical Sciences
    Specialities: psychiatry, pharmacology and brain imaging (especially PET) in relation to addiction and other neuropsychiatric disorders, sleep and hypnotics.
  98. [98]
    Prof Nutt awarded the Outstanding Contribution Award by the BAP
    Jun 27, 2023 · For over 30 years of hard work and energetic commitment to the BAP, we are delighted to nominate Professor David Nutt for the 2023 Outstanding ...
  99. [99]
    Professor David Nutt: oration - University of Bath
    David Nutt is one of the world's leading experts in clinical and preclinical psychopharmacology. ... Psychopharmacology Unit in the University of Bristol.<|separator|>
  100. [100]
    Current status and future challenges for the clinical applications of ...
    Dec 19, 2024 · Professor David Nutt then presented the history and clinical research results to the meeting and how these results supported the proposed ...
  101. [101]
    [PDF] RHD0008 Written evidence submitted by Drug Science
    Nov 14, 2023 · This response has been collated by Drug Science, a charity founded in 2010 by Prof David. Nutt. Drug Science is an independent, science-led ...Missing: causal 2023-2025
  102. [102]
    [PDF] Psychedelic-assisted therapy for mental health: Policy considerations
    Feb 12, 2025 · 12 February 2025. 4. Psychedelic-assisted therapy clinical trials: Regulatory challenges ... David Nutt (2024). Personal communication - David ...
  103. [103]
    David Nutt - X
    Jul 31, 2025 · David Nutt · @ProfDavidNutt · https://drugscience.org.uk/uk-government-supports-acmd-plan… - light at the end of the tunnel for #psychedelics ...
  104. [104]
    David Nutt on X: "Innovative trial will use psilocybin to target relapse ...
    Oct 18, 2024 · David Nutt · @ProfDavidNutt. Innovative trial will use psilocybin to target relapse in opioid addiction - good news from IC. Innovative trial ...
  105. [105]
    Innovations in alcohol-free living - HLK - Haseltine Lake Kempner
    Jan 30, 2025 · One of these compounds is now known as Alcarelle and is a synthetic alcohol molecule. Not yet on the market, it was due to enter the US FDA ...Missing: commercialization | Show results with:commercialization
  106. [106]
    (PDF) Is UK drug policy evidence based? - ResearchGate
    Aug 6, 2025 · In this paper, we examine the extent to which the UK drug strategy can be regarded as evidence-based. Focusing on case studies of policies ...
  107. [107]
    A drink with... Professor David Nutt - Decanter
    Jan 6, 2025 · The botanical drink Sentia stands out for the way it was developed to replicate some of the relaxing, social effects of alcohol, without the alcohol.Missing: commercialization | Show results with:commercialization
  108. [108]
    David Nutt - Drug Science
    At Drug Science we like to cover different topics relating to drugs. These topics cover the many different ways that psychoactive substances have an impact on ...Missing: degree | Show results with:degree
  109. [109]
    Scientist David Nutt on the medical benefits of psychedelic drugs
    Feb 4, 2016 · Nutt settles in a pink velvet armchair. Professor David Nutt and his home in Keynsham, Bristol The family's grand piano © Gareth Iwan Jones.Missing: psychiatrist | Show results with:psychiatrist
  110. [110]
    BBC Radio 3 - Private Passions, David Nutt
    David Nutt. Private Passions. Michael Berkeley's guest is scientist David Nutt. With Grieg, Faure and Beethoven ...